Skip to main content
SpringerLink
Log in

Pharmacological Treatment of Insomnia

  • Chapter
  • First Online:
Clinical Handbook of Insomnia

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

Medications used for the treatment of insomnia include prescription and non-prescription drugs approved by the US Food and Drug Administration (FDA) for the treatment of insomnia, prescription drugs approved by the FDA for treatment of another condition but used “off-label” for the treatment of insomnia, and unregulated substances such as herbal preparations and dietary supplements. These drugs differ in their pharmacological properties and in their efficacy and safety in the treatment of insomnia. This chapter reviews the key pharmacological characteristics of these medications, their mechanisms of action, and the available efficacy and safety data in the treatment of primary and comorbid insomnia. This review is followed by a discussion of the implementation and optimization of pharmacological treatment of insomnia for specific subtypes of insomnia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Walsh JK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep. 2004;27(8):1441–2.

    PubMed  Google Scholar 

  2. Schweitzer PK, Curry DT, Eisenstein RD. Pharmacological treatment of insomnia. In: Attarian H, Schuman C, editors. Clinical handbook of insomnia. 2nd ed. New York: Humana Press; 2010.

    Google Scholar 

  3. Roth T, Rogowski R, Hull S, Schwartz H, Koshorek G, Corser B, Seiden D, Lankford A. Efficacy and safety of doxepin 1, 3 and 6 mg in adults with primary insomnia. Sleep. 2007;30:1555–61.

    PubMed  PubMed Central  Google Scholar 

  4. Buysse D. Clinical pharmacology of other drugs used as hypnotics. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th ed. St. Louis: Elsevier; 2011.

    Google Scholar 

  5. Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev. 2009;13(4):265–74.

    Article  PubMed  Google Scholar 

  6. Stahl S. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 4th ed. New York: Cambridge University Press; 2013.

    Google Scholar 

  7. Miller PS, Aricescu AR. Crystal structure of a human GABAA receptor. Nature. 2014;512(7514):270–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sieghart W, Sperk G. Subunit composition, distribution and function of GABAA receptor subtypes. Curr Topics Med Chem. 2002;2:795–816.

    Article  CAS  Google Scholar 

  9. Olsen RW, Sieghert W. Subtypes of the γ[gamma]-aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacology, and function. Pharmacol Rev. 2008;60(3):243–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, Möhler H. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999;401(6755):796–800.

    Article  CAS  PubMed  Google Scholar 

  11. Li P, Akk G. Synaptic-type α1β2γ2L GABAA receptors produce large persistent currents in the presence of ambient GABA and anesthetic drugs. Mol Pharmacol. 2015;87(5):776–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sieghart W, Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem. 2002;2:795–816.

    Article  CAS  PubMed  Google Scholar 

  13. Sanna E, Busonero F, Talani G, Carta M, Massa F, Peis M, Maciocco E, Biggio G. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes. Eur J Pharmacol. 2002;451:103–10.

    Article  CAS  PubMed  Google Scholar 

  14. Greenblatt DJ, Harmatz JS, Roth T, Singh NN, Moline ML, Harris SC, Kapil RP. Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. Clin Ther. 2013;35(5):604–11.

    Article  CAS  PubMed  Google Scholar 

  15. Neubauer DN. ZolpiMist™: a new formulation of zolpidem tartrate for the short-term treatment of insomnia in the US. Nat Sci Sleep. 2010;2:79–84.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Yang LP, Deeks ED. Sublingual zolpidem (Edluar™; Sublinox™). CNS Drugs. 2012;26(11):1003–10.

    Article  CAS  PubMed  Google Scholar 

  17. Greenblatt DJ, Harmatz JS, Singh NN, Roth T, Harris SC, Kapil RP. Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets. J Clin Pharmacol. 2013;53(11):1194–8.

    CAS  PubMed  Google Scholar 

  18. Wang JS, DeVane CL. Pharmacokinetics and drug interactions of the sedative hypnotics. Psychopharmacol Bull. 2003;37(1):10–29.

    PubMed  Google Scholar 

  19. Von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, Shader RI. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol. 1999;48:89–97.

    Article  Google Scholar 

  20. Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Tateishi T, Otani K. Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity. Ther Drug Monit. 2004;26(5):529–33.

    Article  CAS  PubMed  Google Scholar 

  21. Greenblatt DJ, Harmatz JS, Singh NN, Steinberg F, Roth T, Moline ML, Harris SC, Kapil RP. Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. J Clin Pharmacol. 2014;54(3):282–90.

    Article  CAS  PubMed  Google Scholar 

  22. Schwarz HJ. Pharmacokinetics and metabolism of temazepam in man and several animal species. Br J Clin Pharmacol. 1979;8:23S–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, Scatina JA. Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica. 2002;32(10):835–47.

    Article  CAS  PubMed  Google Scholar 

  24. Renwick AB, Ball SE, Tredger JM, Price RJ, Walters DG, Kao J, Scatina JA, Lake BG. Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica. 2002;32(10):849–62.

    Article  CAS  PubMed  Google Scholar 

  25. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26:793–9.

    PubMed  Google Scholar 

  26. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life and work limitations. Sleep. 2007;30:959–68.

    PubMed  PubMed Central  Google Scholar 

  27. Roth T, Walsh J, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6:487–95.

    Article  PubMed  Google Scholar 

  28. Krystal AD, Erman M, Zammit GK, et al. ZOLONG Study Group. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008; 31:79–90.

    Google Scholar 

  29. Ancoli-Israel S, Richardson GS, Mangano RM, Jenkins L, Hall P, Jones WS. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med. 2005;6(2):107–13.

    Article  PubMed  Google Scholar 

  30. Perlis M, McCall WV, Krystal A, et al. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry. 2004;65:1128–37.

    Article  CAS  PubMed  Google Scholar 

  31. Walsh JK, Vogel GW, Scharf M, Erman M, William Erwin C, Schweitzer PK, Mangano RM, Roth T. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med. 2000;1(1):41–9.

    Article  PubMed  Google Scholar 

  32. Zammit GK, Corser B, Doghramji K, Fry JM, James S, Krystal A, Mangano RM. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. J Clin Sleep Med. 2006;2(4):417–23.

    PubMed  Google Scholar 

  33. Walsh JK, Muehlbach MJ, Lauter SA, Hilliker NA, Schweitzer PK. Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis. J Rheumatol. 1996;23(2):245–52.

    CAS  PubMed  Google Scholar 

  34. Asnis GM, Chakraburtty A, DuBoff EA, Krystal A, Londborg PD, Rosenberg R, Roth-Schechter B, Scharf MB, Walsh JK. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry. 1999;60(10):668–76.

    Article  CAS  PubMed  Google Scholar 

  35. Fava M, Asnis GM, Shrivastava R, Lydiard B, Bastani B, Sheehan D, Roth T. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol. 2009;29(3):222–30.

    Article  CAS  PubMed  Google Scholar 

  36. Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, Roth T. Improved insomnia symptoms and sleep-related next day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry. 2011;72(7):914–28.

    Article  CAS  PubMed  Google Scholar 

  37. Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008;65(5):551–62.

    Article  CAS  PubMed  Google Scholar 

  38. Fava M, McCall WV, Krystal A, Rubens R, Caron J, Wessel T, Amato T, Roth T. Eszopiclone coadministered with fluoxetine in patients with insomnia co-existing with major depressive disorder. Biol Psychiatry. 2006;59(11):1052–60.

    Google Scholar 

  39. Dorsey CM, Lee KA, Scharf MB. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther. 2004;26(10):1578–86.

    Article  CAS  PubMed  Google Scholar 

  40. Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol. 2006;108(6):1402–10.

    Article  CAS  PubMed  Google Scholar 

  41. Goforth HW, Preud’homme XA, Krystal AD. A randomized, double-blind, placebo-controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep. 2014;37(6):1053–60.

    PubMed  PubMed Central  Google Scholar 

  42. Roth T, Price JM, Amato DA, Rubens RP, Roach JM, Schnitzer TJ. The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Prim Care Companion J Clin Psychiatry. 2009;11(6):292.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Pollack MH, Hoge EA, Worthington JJ, Moshier SJ, Wechsler RS, Brandes M, Simon NM. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(7):892–7.

    Article  CAS  PubMed  Google Scholar 

  44. Tek C, Palmese LB, Krystal AD, Srihari VH, DeGeorge PC, Reutenauer EL, Guloksuz S. The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial. Schizophr Res. 2014;160(1–3):180–5.

    Article  PubMed  Google Scholar 

  45. Bliwise D, Seidel W, Karacan I, Mitler M, Roth T, Zorick F, Dement W. Daytime sleepiness as a criterion in hypnotic medication trials: comparison of triazolam and flurazepam. Sleep. 1983;6(2):156–63.

    CAS  PubMed  Google Scholar 

  46. Roehrs TA, Roth T. Gender differences in the efficacy and safety of chronic nightly zolpidem. J Clin Sleep Med. 2016;12(3):319–25.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Walsh JK, Schweitzer PK, Sugerman JL, Muehlbach MJ. Transient insomnia associated with a 3-hour phase advance of sleep time and treatment with zolpidem. J Clin Psychopharmacol. 1990;10(3):184–9.

    Article  CAS  PubMed  Google Scholar 

  48. Walsh JK, Pollak CP, Scharf MB, Schweitzer PK, Vogel GW. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol. 2000;23(1):17–21.

    Article  CAS  PubMed  Google Scholar 

  49. Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB, Intermezzo Study Group. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep. 2008;31(9):1277–84.

    PubMed  PubMed Central  Google Scholar 

  50. Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297–328.

    Article  CAS  PubMed  Google Scholar 

  51. Verster JC, Volkerts ER, Schreuder AH, Eijken EJ, van Heuckelum JH, Veldhuijzen DS, Verbaten MN, Paty I, Darwish M, Danjou P, Patat A. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol. 2002;22(6):576–83.

    Article  CAS  PubMed  Google Scholar 

  52. Vermeeren A, Vuurman EF, Leufkens TR, Van Leeuwen CJ, Van Oers AC, Laska E, Rico S, Steinberg F, Roth T. Residual effects of low-dose sublingual zolpidem on highway driving performance the morning after middle-of-the-night use. Sleep. 2014;37(3):489–96.

    PubMed  PubMed Central  Google Scholar 

  53. Leufkens TR, Lund JS, Vermeeren A. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res. 2009;18(4):387–96.

    Article  PubMed  Google Scholar 

  54. Leufkens TR, Ramaekers JG, de Weerd AW, Riedel WJ, Vermeeren A. Residual effects of zopiclone 7.5mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study. Psychopharmacology. 2014;231:2785–98.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Staner L, Ertlé S, Boeijinga P, Rinaudo G, Arnal MA, Muzet A, Luthringer R. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology (Berl). 2005;181(4):790–8.

    Article  CAS  Google Scholar 

  56. Partinen M, Hirvonen K, Hublin C, Halavaara M, Hiltunen H. Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. Sleep Med. 2003;4(6):553–61.

    Article  CAS  PubMed  Google Scholar 

  57. Brassington GS, King AC, Bliwise DL. Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64–99 years. J Am Geriatr Soc. 2000;48(10):1234–40.

    Article  CAS  PubMed  Google Scholar 

  58. Helbig AK, Döring A, Heier M, Emeny RT, Zimmermann AK, Autenrieth CS, Ladwig KH, Grill E, Meisinger C. Association between sleep disturbances and falls among the elderly: results from the German Cooperative Health Research in the Region of Augsburg-Age study. Sleep Med. 2013;14(12):1356–63.

    Article  PubMed  Google Scholar 

  59. Kuo HK, Yang CC, Yu YH, Tsai KT, Chen CY. Gender-specific association between self-reported sleep duration and falls in high-functioning older adults. J Gerontol A Biol Sci Med Sci. 2010;65(2):190–6.

    Article  PubMed  Google Scholar 

  60. Avidan AY, Fries BE, James ML, Szafara KL, Wright GT, Chervin RD. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc. 2005;53(6):955–62.

    Article  PubMed  Google Scholar 

  61. Ham AC, Swart KM, Enneman AW, van Dijk SC, Oliai Araghi S, van Wijngaarden JP, van der Zwaluw NL, Brouwer-Brolsma EM, Dhonukshe-Rutten RA, van Schoor NM, van der Cammen TJ, Lips P, de Groot LC, Uitterlinden AG, Witkamp RF, Stricker BH, van der Velde N. Medication-related fall incidents in an older, ambulant population: the B-PROOF study. Drugs Aging. 2014;31(12):917–27.

    Article  CAS  PubMed  Google Scholar 

  62. Ensrud KE, Blackwell TL, Mangione CM, Bowman PJ, Whooley MA, Bauer DC, Schwartz AV, Hanlon JT, Nevitt MC, Study of Osteoporotic Fractures Research Group. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc. 2002;50(10):1629–37.

    Article  PubMed  Google Scholar 

  63. Richardson K, Bennett K, Kenny RA. Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults. Age Ageing. 2015;44(1):90–6.

    Article  PubMed  Google Scholar 

  64. Kelly KD, Pickett W, Yiannakoulias N, Rowe BH, Schopflocher DP, Svenson L, Voaklander DC. Medication use and falls in community-dwelling older persons. Age Ageing. 2003;32(5):503–9.

    Article  PubMed  Google Scholar 

  65. Diem SJ, Ewing SK, Stone KL, Ancoli-Israel S, Redline S, Ensrud KE. The Osteoporotic Fractures in Men (MrOS) Study Group. Use of non-benzodiazepine sedative hypnotics and risk of falls in older men. J Gerontol Geriatr Res. 2014;3(3):158.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med. 2013;173(9):754–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med. 1991;324(24):1691–8.

    Article  CAS  PubMed  Google Scholar 

  68. Roth T, Roehrs TA, Stepanski EJ, Rosenthal LD. Hypnotics and behavior. Am J Med. 1990;88(3A):43S–6.

    Article  CAS  PubMed  Google Scholar 

  69. Uemura SI, Kanbayashi T, Wakasa M, Satake M, Ito W, Shimizu K, Shioya T, Shimizu T, Nishino S. Residual effects of zolpidem, triazolam, rilmazafone and placebo in healthy elderly subjects: a randomized double-blind study. Sleep Med. 2015;16(11):1395–402.

    Article  PubMed  Google Scholar 

  70. Kleykamp BA, Griffiths RR, McCann UD, Smith MT, Mintzer MZ. Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use. Exp Clin Psychopharmacol. 2012;20(1):28–39.

    Article  CAS  PubMed  Google Scholar 

  71. Troy SM, Lucki I, Unruh MA, Cevallos WH, Leister CA, Martin PT, Furlan PM, Mangano R. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol. 2000;20(3):328–37.

    Article  CAS  PubMed  Google Scholar 

  72. Roehrs T, Zorick FJ, Sicklesteel JM, Wittig RM, Hartse KM, Roth T. Effects of hypnotics on memory. J Clin Psychopharmacol. 1983;3(5):310–3.

    Article  CAS  PubMed  Google Scholar 

  73. Yang W, Dollear M, Muthukrishnan SR. One rare side effect of zolpidem—sleepwalking: a case report. Arch Phys Med Rehabil. 2005;86(6):1265–6.

    Article  PubMed  Google Scholar 

  74. Harazin J, Berigan TR. Zolpidem tartrate and somnambulism. Mil Med. 1999;164(9):669–70.

    CAS  PubMed  Google Scholar 

  75. Chen YW, Tseng PT, Wu CK, Chen CC. Zaleplon-induced anemsic somnambulism with eating behaviors under once dose. Acta Neurol Taiwan. 2014;23(4):143–5.

    PubMed  Google Scholar 

  76. Poceta JS. Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. J Clin Sleep Med. 2011;7(6):632–8.

    PubMed  PubMed Central  Google Scholar 

  77. Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs. 2008;22(12):1021–36.

    Article  CAS  PubMed  Google Scholar 

  78. Usumoto Y, Kudo K, Sameshima N, Sato K, Tsuji A, Ikeda N. An autopsy case of abnormal behaviour induced by zolpidem. Fukuoka Igaku Zasshi. 2015;106(6):202–5.

    PubMed  Google Scholar 

  79. Chen CS, Huang MF, Hwang TJ, Chen ST, Ko CH, Yen CN, Chen TT, Su PW, Yeh YC, Lin JJ, Yen CF. Clinical correlates of zolpidem-associated complex sleep-related behaviors: age effect. J Clin Psychiatry. 2014;75(11):e1314–8.

    Article  PubMed  Google Scholar 

  80. Kay-Stacey M, Attarian H. Advances in the management of chronic insomnia. Br Med J. 2016 (In Press).

    Google Scholar 

  81. Kripke DF, Langer RD, Kline LE. Hypnotics’ association with mortality or cancer: a matched cohort study. BMJ Open. 2012;2(1):e000850.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Lallukka T, Podlipskyte A, Sivertsen B, et al. Insomnia symptoms and mortality: a register-linked study among women and men from Finland, Norway and Lithuania. J Sleep Res. 2015. doi:10.1111/jsr.12343.

    Google Scholar 

  83. Kriegbaum M, Hendriksen C, Vass M, et al. Hypnotics and mortality—partial confounding by disease, substance abuse and socioeconomic factors? Pharmacoepidemiol Drug Saf. 2015;24(7):779–83.

    Article  PubMed  Google Scholar 

  84. Jaussent I, Ancelin ML, Berr C, et al. Hypnotics and mortality in an elderly general population: a 12-year prospective study. BMC Med. 2013;11:212.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Neutel CI, Johansen HL. Association between hypnotics use and increased mortality: causation or confounding? Eur J Clin Pharmacol. 2015;71:637–42.

    Article  CAS  PubMed  Google Scholar 

  86. Roehrs TA, Randall S, Harris E, Maan R, Roth T. Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study. Sleep. 2011;34(2):207–12.

    PubMed  PubMed Central  Google Scholar 

  87. Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, Schweitzer PK, Ware JC. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep. 2000;23(8):1087–96.

    CAS  PubMed  Google Scholar 

  88. Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry. 1992;53(Suppl):34–9. discussion 40–42.

    PubMed  Google Scholar 

  89. Licata SC, Penetar DM, Dunlap S, Lukas SE. A therapeutic dose of zolpidem has limited abuse-like effects in drug-naïve females: a pilot study. Eur J Pharmacol. 2008;598(1–3):64–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther. 1990;255(3):1246–55.

    CAS  PubMed  Google Scholar 

  91. Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology (Berl). 1999;144(3):220–33.

    Article  CAS  Google Scholar 

  92. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry. 2005;66 Suppl 9:31–41.

    CAS  PubMed  Google Scholar 

  93. Becker WC, Fiellin DA, Desai RA. Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend. 2007;90:280–7.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia—a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry. 1994;27(4):166–75.

    Article  CAS  PubMed  Google Scholar 

  95. Roehrs T, Merlotti L, Zorick F, et al. Rebound insomnia and hypnotic self administration. Psychopharmacology. 1992;107:480–4.

    Article  CAS  PubMed  Google Scholar 

  96. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48(2):301–10.

    Article  CAS  PubMed  Google Scholar 

  97. Miayamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel drug for sleep disorders. CNS Neurosci Ther. 2009;15:32–51.

    Article  CAS  Google Scholar 

  98. Erman M, Seiden D, Zammit G, Sainati S, Zheng J. An efficacy, safety and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7:17–24.

    Article  PubMed  Google Scholar 

  99. Mayer G, Wang-Wiegand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M. Efficacy and safety of 6-month nightly ramnelteon administration in adults with primary insomnia. Sleep. 2009;32(3):351–60.

    PubMed  PubMed Central  Google Scholar 

  100. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006;7:312–8.

    Article  PubMed  Google Scholar 

  101. Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med. 2014;15:385–92.

    Article  PubMed  Google Scholar 

  102. Winrow CJ. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet. 2011;25:52–61.

    Article  CAS  PubMed  Google Scholar 

  103. de Lecea L, Huerta R. Hypocretin (orexin) regulation of sleep-to-wake transitions. Front Pharmacol. 2014;5:16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Riemann D, Spiegelhalder K, Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev. 2010;14:19–31.

    Article  PubMed  Google Scholar 

  105. Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36:259–67.

    PubMed  PubMed Central  Google Scholar 

  106. Herring W, Connor K, Ivgy-May N, Snyder E, Liu K, Snavely D, Krystal A, Walsh J, Benca R, Rosenberg R, Sangal R, Budd K, Hutzelmann J, Liebensperger H, Froman S, Lines C, Roth T, Michelson D. Suvorexant in patients with insomnia: results from two 3-month randomized clinical trials. Biol Psychiatry. http://dx.doi.org/10.1016/j.biopsych.2014.10.003

  107. Michelson D, Snyder E, Paradis E, Chengan-Liu M, Hutzelman J, Walsh J, Krystal A, Benca R, Cohn M, Lines C, Roth T, Herring W. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:461–71.

    Article  CAS  PubMed  Google Scholar 

  108. Herring W, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79:2265–74.

    Article  CAS  PubMed  Google Scholar 

  109. Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep. 2014;37(10):1609–19.

    PubMed  PubMed Central  Google Scholar 

  110. Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner J, Troyer M. Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea. J Clin Sleep Med. 2016;12(1):9–17.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rose J, Lines C, Wagner J, Troyer M. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109(3):416–26. doi:10.1016/j.rmed.2014.12.010. Epub 2015 Jan 5.

    Article  PubMed  Google Scholar 

  112. Vermeeren A, Sun H, Vuurman E, Jongen S, Van Leeuwen C, Van Oers A, Palcza J, Li X, Laethem T, Heirman I, Bautmans A, Troyer M, Wrishko R, McCrea J. On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers. Sleep. 2015;38(11):1803–13.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Weber J, Siddiqui M, Wagstaff A. Low-dose doxepin: in the treatment of insomnia. CNS Drugs. 2010;24:713–20.

    Article  CAS  PubMed  Google Scholar 

  114. Krystal AD, Richelson E, Roth T. Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications. Sleep Med Rev. 2013;17(4):263–72.

    Article  PubMed  Google Scholar 

  115. Krystal AD, Lankford A, Durrence HH, Ludington E, Jochelson P, Rogowski R, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34:1433–42.

    PubMed  PubMed Central  Google Scholar 

  116. Krystal AD, Durrence HH, Scharf M, Jochelson P, Rogowski R, Ludington E, et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep. 2010;33:1553–61.

    PubMed  PubMed Central  Google Scholar 

  117. Rickels K, Morris RJ, Newman H, Rosenfeld H, Schiller H, Weinstock R. Diphenhydramine in insomniac family practice patients: a double-blind study. J Clin Pharmacol. 1983;23(5–6):234–42.

    Article  CAS  PubMed  Google Scholar 

  118. Morin C, Koetter U, Bastien C, Ware JC, Wooten V. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep. 2005;28(11):1465–71.

    PubMed  Google Scholar 

  119. Zhang D, Tashiro M, Shibuya K, Okamura N, Funake Y, Yoshikawa T, Kato M, Yanai K. Next day residual sedative effect after nighttime administration of an over-the-countere antihistamine sleep aid, diphenhydramine, measured by positron emission tomography. J Clin Psychopharm. 2010;30(6):694–701.

    Article  CAS  Google Scholar 

  120. Schweitzer PK, Muehlbach MJ, Walsh JK. Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immunol. 1994;94:716–24.

    Article  CAS  PubMed  Google Scholar 

  121. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol. 2002;22:511–5.

    Article  CAS  PubMed  Google Scholar 

  122. Roehrs T, Roth T. ‘Hypnotic’ prescription patterns in a large managed-care population. Sleep Med. 2004;5(5):463–6.

    Article  PubMed  Google Scholar 

  123. Ferri R, Zucconi M, Marelli S, Plazzi G, Schenck CH, Ferini-Strambi L. Effects of long-term use of clonazepam on nonrapid eye movement sleep patterns in rapid eye movement sleep behavior disorder. Sleep Med. 2013;14(5):399–406.

    Article  PubMed  Google Scholar 

  124. Walsh J, Erman M, Erwin C, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum Psychopharmacol. 1998;13:191–8.

    Article  CAS  Google Scholar 

  125. Roth A, McCall W, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011;20:552–8.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Le Bon O, Murphy JR, Staner L, Hoffmann G, Kormoss N, Kentos M, Dupont P, Lion K, Pelc I, Verbanck P. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol. 2003;23(4):377–83.

    Article  PubMed  CAS  Google Scholar 

  127. Friedmann PD, Rose JS, Swift R, Stout RL, Millman RP, Stein MD. Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2008;32(9):1652–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Stein MD, Kurth ME, Sharkey KM, Anderson BJ, Corso RP, Millman RP. Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial. Drug Alcohol Depend. 2012;120(1–3):65–73.

    Article  CAS  PubMed  Google Scholar 

  129. Nierenberg A, Adler L, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151:1069–72.

    Article  CAS  PubMed  Google Scholar 

  130. Ivgy-May N, Ruwe F, Krystal A, Roth T. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety form a randomized, 6-week sleep laboratory trial. Sleep Med. 2015;16:838–44.

    Article  PubMed  Google Scholar 

  131. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998;51(3):267–85.

    Article  CAS  PubMed  Google Scholar 

  132. Rodenbeck A, Cohrs S, Jordan W, Huether G, Ruther E, Hajak G. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. Psychopharmacology (Berl). 2003;170:423–8.

    Article  CAS  Google Scholar 

  133. Hajak G, Rodenbeck A, Adler L, Huether G, Bandelow B, Herrendorf G, Staedt J, Rüther E. Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry. 1996;29(5):187–92.

    Article  CAS  PubMed  Google Scholar 

  134. Hajak G, Rodenbeck A, Voderholzer U, Riemann D, Cohrs S, Hohagen F, Berger M, Rüther E. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry. 2001;62(6):453–63.

    Article  CAS  PubMed  Google Scholar 

  135. Riemann D, Voderholzer U, Cohrs S, Rodenbeck A, Hajak G, Ruther E, Wiegand M, Laakmann G, Baghai T, Fischer W, Hoffmann M, Hohagen F, Mayer G, Berger M. Trimipramine in primary insomnia: results of a polysomographic double-blind controlled study. Pharmacopsychiatry. 2002;35(5):165–74.

    Article  CAS  PubMed  Google Scholar 

  136. Hohagen F, Montero RF, Weiss E. Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci. 1994;244(2):65–72.

    Article  CAS  PubMed  Google Scholar 

  137. Kupfer DJ, Spiker DG, Coble P, et al. Amitriptyline and EEG sleep in depressed patients: I. Drug effect. Sleep. 1978;1:149–59.

    CAS  PubMed  Google Scholar 

  138. Roth T, Zorick F, Wittig R, McLenaghan A, Roehrs T. The effects of doxepin HCl on sleep and depression. J Clin Psychiatry. 1982;43(9):366–8.

    CAS  PubMed  Google Scholar 

  139. Ware JC, Brown FW, Moorad Jr PJ, Pittard JT, Cobert B. Effects on sleep: a double-blind study comparing trimipramine to imipramine in depressed insomniac patients. Sleep. 1989;12(6):537–49.

    CAS  PubMed  Google Scholar 

  140. Rios Romenets S, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, Postuma RB. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease—a randomized study. Parkinsonism Relat Disord. 2013;19(7):670–5.

    Article  CAS  PubMed  Google Scholar 

  141. Nelson JC. Tricyclic and tetracyclic drugs. In: Schatzberg Am Nemeroff C, editor. The American Psychiatric Publishing textbook of psychopharmacology. Washington, DC: American Psychiatric Publishing; 2004. p. 207–20.

    Google Scholar 

  142. Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai. 2010;93(6):729–34.

    PubMed  Google Scholar 

  143. Wiegand M, Landry T, Bruckner T, Pohl C, Zdenko V, Jahn T. Quetiapine in primary insomnia: a pilot study. Psychopharmacology. 2008;196:337–8.

    Article  CAS  PubMed  Google Scholar 

  144. Anderson S, Vande GJ. Quetiapine for insomnia: a review of the literature. Am J Health Syst Pharm. 2014;71:394–402.

    Article  CAS  PubMed  Google Scholar 

  145. Trivedi M, Bandelow B, Demyttenaere K, Papakosts G, Szamosi J, Earley W, Eriksson H. Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. Int J Neuropsychopharmacol. 2013;16:1733–44.

    Article  CAS  PubMed  Google Scholar 

  146. Endicott J, Paulsson B, Gustafsson U, et al. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. J Affect Disord. 2008;111:306–19.

    Article  CAS  PubMed  Google Scholar 

  147. Stein D, Bandelow B, Merideth C, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder: an analysis of pooled data from 3 8-week placebo-controlled studies. Hum Psychopharmacol. 2011;26:614–28.

    Article  CAS  PubMed  Google Scholar 

  148. Potvin S, Morin M, Cloutier C, Gendron A, Bissonnette A, Marchand D. Add-on treatment of quetiapine for fibromyalgia. A pilot, randomized, double-blind, placebo-controlled 12-week trial. J Clin Psychopharmacol. 2012;32:684–7.

    Article  CAS  PubMed  Google Scholar 

  149. Cates ME, Jackson CW, Feldman JM, et al. Metabolic consequences of using low dose quetiapine for insomnia in psychiatric patients. Community Ment Health J. 2009;45:251–4.

    Article  PubMed  Google Scholar 

  150. Gugger JJ, Cassagnol M. Low-dose quetiapine is not a benign sedative-hypnotic agent. Am J Addict. 2008;17:454–5.

    Article  PubMed  Google Scholar 

  151. Coe HV, Hong IS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother. 2012;46:718–22.

    Article  PubMed  CAS  Google Scholar 

  152. Kirshner H. Controversies in behavioral neurology: the use of atypical antipsychotic drugs to treat neurobehavioral symptoms in dementia. Curr Neurol Neurosci Rep. 2008;8(6):471–4.

    Article  CAS  PubMed  Google Scholar 

  153. Rose M, Kam CA. Gabapentin: pharmacology and it’s use in pain management. Anaesthesia. 2002;57:451–62.

    Article  CAS  PubMed  Google Scholar 

  154. Gajraj N. Pregabalin: its pharmacology and use in pain management. Anesth Analg. 2007;105(6):1805–15.

    Article  CAS  PubMed  Google Scholar 

  155. Rosenberg R, Hull S, Lankford D, Mayleben D, Seiden D, Furey S, Jayawardena S, Roth T. A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. J Clin Sleep Med. 2014;10(10):1093–100.

    PubMed  PubMed Central  Google Scholar 

  156. Furey S, Hull S, Leibowitz MT, Jayawardena S, Roth T. A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. J Clin Sleep Med. 2014;10(10):1101–9.

    PubMed  PubMed Central  Google Scholar 

  157. Lo H-S, Yang C-M, Lo H, Lee C-Y, Ting H, Tzang B-S. Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol. 2010;22:84–90.

    Article  CAS  Google Scholar 

  158. Winkelman J, Bogan R, Schmidt M, Hudson J, DeRossett S, Hill-Zabala C. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord. 2011;26(11):2065–72.

    Article  PubMed  Google Scholar 

  159. Garcia-Borreguero D, Patrick J, DuBrava S, Becker P, Lankford A, Chen C, Miceli J, Knapp L, Allen R. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep. 2014;37(4):635–43.

    PubMed  PubMed Central  Google Scholar 

  160. Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck Jr PE, Welge JA, Bishop F, Stanford KE, Hess EV, Hudson JI. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336–44.

    Article  CAS  PubMed  Google Scholar 

  161. Roth T, Lankford D, Bhadra P, Whalen E, Resnick E. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover Polysomnography study. Arthritis Care Res (Hoboken). 2012;64(4):597–606.

    Article  CAS  Google Scholar 

  162. Sabatowski R, Gálvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, Versavel M, 1008–045 Study Group. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109(1–2):26–35.

    Article  CAS  PubMed  Google Scholar 

  163. Boyle J, Eriksson ME, Gribble L, Gouni R, Johnsen S, Coppini DV, Kerr D. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012;35(12):2451–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Yurcheshen ME, Guttuso Jr T, McDermott M, Holloway RG, Perlis M. Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model. J Womens Health (Larchmt). 2009;18(9):1355–60.

    Article  Google Scholar 

  165. De Haas S, Otte A, de Weerd A, van Erp G, Cohen A, van Gerven J. Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy. J Clin Sleep Med. 2007;3(5):473–8.

    PubMed  PubMed Central  Google Scholar 

  166. Roth T, Arnold L, Garcia-Borreguero D, Resnick M, Clair A. A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. Sleep Med Rev. 2014;18(3):261–71.

    Article  PubMed  Google Scholar 

  167. Walsh JK, Perlis M, Rosenthal M, Krystal A, Jiang J, Roth T. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med. 2006;2(1):35–41.

    PubMed  Google Scholar 

  168. Walsh JK, Randazzo AC, Frankowski S, Shannon K, Schweitzer PK, Roth T. Dose-response effects of tiagabine on the sleep of older adults. Sleep. 2005;28(6):673–6.

    PubMed  Google Scholar 

  169. Krystal AD. New developments in insomnia medications of relevance to mental health disorders. Psychiatr Clin N Am. 2015;38:843–60.

    Article  Google Scholar 

  170. Irwin M, Clark C, Kennedy B, et al. Nocturnal catecholamines and immune function in insomniacs, depressed patients, and control subjects. Brain Behav Immun. 2003;17(5):365–72.

    Article  CAS  PubMed  Google Scholar 

  171. Germain A, Richardson R, Moul DE, Mammen O, Haas G, Forman SD, Rode N, Begley A, Nofzinger EA. Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US Military Veterans. J Psychosom Res. 2012;72(2):89–96.

    Article  PubMed  Google Scholar 

  172. Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007;61(8):928–34.

    Article  CAS  PubMed  Google Scholar 

  173. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, Dobie DJ, Hoff D, Rein RJ, Straits-Tröster K, Thomas RG, McFall MM. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2):371–3.

    Article  PubMed  Google Scholar 

  174. Raskind MA, Peterson K, Williams T, et al. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry. 2013;170(9):1003–10.

    Article  PubMed  Google Scholar 

  175. Taylor FB, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry. 2008;63(6):629–32.

    Article  CAS  PubMed  Google Scholar 

  176. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino Jr JS. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000;40:781–4.

    Article  CAS  PubMed  Google Scholar 

  177. Ferracioli-Oda E, Qawasmi A, Bloch M. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5), e63773. doi:10.1371/journal.pone.0063773.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  178. Wilson S, Nutt D, Alford C, Argyropoulos S, Baldwin D, Bateson A, Britton T, Crowe C, Dijk D-J, Espie C, Gringras P, Hajak G, Idzikowski C, Krystal A, Nash J, Selsick H, Sharpley A, Wade A. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;23(11):1577–600.

    Article  Google Scholar 

  179. Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010;8:51. doi:10.1186/1741-7015-8-51.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  180. Van Geijlswijk IM, Korzilius HP, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep. 2010;33(12):1605–14.

    PubMed  PubMed Central  Google Scholar 

  181. Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med. 2005;20:1151–8.

    Article  PubMed  PubMed Central  Google Scholar 

  182. Committee on the Framework for Evaluating the Safety of the Dietary Supplements FaNB, Board on Life Sciences, Institute of Medicine and National Research Council of the National Academies. Dietary supplements: a framework for evaluating safety. Washington, DC: The National Academies Press; 2005.

    Google Scholar 

  183. Auger RRA, Burgess HJ, Emens JS, Deriy L, Thomas SM, Sharkey K. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleep-wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD). An update for 2015. An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2015;11(10):1199–236.

    Article  PubMed  PubMed Central  Google Scholar 

  184. Shekleton JA, Flynn-Evans EE, Miller B, Epstein LJ, Kirsch D, Brogna LA, Burke LM, Bremer E, Murray JM, Gehrman P, Lockley SW, Rajaratnam SM. Neurobehavioral performance impairment in insomnia: relationships with self-reported sleep and daytime functioning. Sleep. 2014;37(1):107–16.

    PubMed  PubMed Central  Google Scholar 

  185. Zammit GK, Weiner J, Damata N, et al. Quality of life in people with insomnia. Sleep. 1999;22 Suppl 2:S379–85.

    PubMed  Google Scholar 

  186. Breslau N, Roth T, Rosenthal L, et al. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39:411–8.

    Article  CAS  PubMed  Google Scholar 

  187. Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep. 2007;30:263–73.

    PubMed  Google Scholar 

  188. Shahly V, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shillington AC, Stephenson JJ, Walsh JK, Kessler RC. The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. Arch Gen Psychiatry. 2012;69(10):1054–63.

    Article  PubMed  Google Scholar 

  189. Kucharczyk ER, Morgan K, Hall AP. The occupational impact of sleep quality and insomnia symptoms. Sleep Med Rev. 2012;16(6):547–59.

    Article  PubMed  Google Scholar 

  190. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487–504.

    Google Scholar 

  191. Dolly FR, Block AJ. Effect of flurazepam on sleep-disordered breathing and nocturnal oxygen desaturation in asymptomatic subjects. Am J Med. 1982;73(2):239–43.

    Article  CAS  PubMed  Google Scholar 

  192. Rosenberg R, Roach JM, Scharf M, Amato DA. A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Med. 2007;8(5):464–70.

    Article  PubMed  Google Scholar 

  193. Eckert DJ, Owens RL, Kehlmann GB, Wellman A, Rahangdale S, Yim-Yeh S, White DP, Malhotra A. Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold. Clin Sci (Lond). 2011;120(12):505–14.

    Article  Google Scholar 

  194. Quadri S, Drake C, Hudgel DW. Improvement of idiopathic central sleep apnea with zolpidem. J Clin Sleep Med. 2009;5(2):122–9.

    PubMed  PubMed Central  Google Scholar 

  195. Steens RD, Pouliot Z, Millar TW, Kryger MH, George CF. Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep. 1993;16(4):318–26.

    CAS  PubMed  Google Scholar 

  196. Timms RM, Dawson A, Hajdukovic RM, Mitler MM. Effect of triazolam on sleep and arterial oxygen saturation in patients with chronic obstructive pulmonary disease. Arch Intern Med. 1988;148(10):2159–63.

    Article  CAS  PubMed  Google Scholar 

  197. Lettieri CJ, Shah AA, Holley AB, Kelly WF, Chang AS, Roop SA, CPAP Promotion and Prognosis-The Army Sleep Apnea Program Trial. Effects of a short course of eszopiclone on continuous positive airway pressure adherence: a randomized trial. Ann Intern Med. 2009;151(10):696–702.

    Article  PubMed  Google Scholar 

  198. Roehrs T, Merlotti L, Zorick F, Roth T. Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation. Psychopharmacology (Berl). 1992;108(1–2):67–71.

    Article  CAS  Google Scholar 

  199. Bélanger L, Vallières A, Ivers H, Moreau V, Lavigne G, Morin CM. Meta-analysis of sleep changes in control groups of insomnia treatment trials. J Sleep Res. 2007;16(1):77–84.

    Article  PubMed  Google Scholar 

  200. Winkler A, Rief W. Effect of placebo conditions on polysomnographic parameters in primary insomnia: a meta-analysis. Sleep. 2015;38(6):925–31.

    PubMed  PubMed Central  Google Scholar 

  201. Walsh JK, Coulouvrat C, Hajak G, Lakoma MD, Petukhova M, Roth T, Sampson NA, Shahly V, Shillington A, Stephenson JJ, Kessler RC. Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). Sleep. 2011;34(8):997–1011.

    PubMed  PubMed Central  Google Scholar 

  202. Krystal AD, Benca R, Kilduff T. Understanding the sleep-wake cycle: sleep, insomnia, and the orexin system. J Clin Psychiatry. 2013;74 Suppl 1:3–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

The authors gratefully acknowledge the assistance of Angela C. Randazzo, Ph.D., in the preparation of this chapter.

Author information

Authors and Affiliations

  1. Sleep Medicine and Research Center, St. Luke’s Hospital, 232 S. Woods Mill Road, Chesterfield, MO, 63017, USA

    Paula K. Schweitzer Ph.D.

  2. Department of Neurology and Sleep Medicine, Kaiser Permanente, Atlanta, GA, USA

    Stephen D. Feren M.D.

Authors
  1. Paula K. Schweitzer Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen D. Feren M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paula K. Schweitzer Ph.D. .

Editor information

Editors and Affiliations

  1. Sleep Disorders Center, Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

    Hrayr P. Attarian

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Schweitzer, P.K., Feren, S.D. (2017). Pharmacological Treatment of Insomnia. In: Attarian, H. (eds) Clinical Handbook of Insomnia. Current Clinical Neurology. Springer, Cham. https://doi.org/10.1007/978-3-319-41400-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-41400-3_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-41398-3

  • Online ISBN: 978-3-319-41400-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation